These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32532121)

  • 21. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR
    Drugs Aging; 2003; 20(3):175-83. PubMed ID: 12578398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials.
    Teleni L; Chan RJ; Chan A; Isenring EA; Vela I; Inder WJ; McCarthy AL
    Endocr Relat Cancer; 2016 Feb; 23(2):101-12. PubMed ID: 26584972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update.
    Owen PJ; Daly RM; Livingston PM; Fraser SF
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):137-145. PubMed ID: 28117386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteoporosis during androgen deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
    Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
    BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
    Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
    BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteoporosis due to androgen deprivation therapy in men with prostate cancer.
    Daniell HW
    Urology; 2001 Aug; 58(2 Suppl 1):101-7. PubMed ID: 11502461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
    Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
    BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
    Kiratli BJ; Srinivas S; Perkash I; Terris MK
    Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone health and its correlates in Korean prostate cancer patients receiving androgen deprivation therapy.
    Kim SH; Seong do H; Yoon SM; Choi YD; Song Y; Song H; Choi E
    Eur J Oncol Nurs; 2016 Apr; 21():197-204. PubMed ID: 26522218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen deprivation therapy for prostate cancer results in significant loss of bone density.
    Wei JT; Gross M; Jaffe CA; Gravlin K; Lahaie M; Faerber GJ; Cooney KA
    Urology; 1999 Oct; 54(4):607-11. PubMed ID: 10510915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Muscle and bone effects of androgen deprivation therapy: current and emerging therapies.
    Cheung AS; Zajac JD; Grossmann M
    Endocr Relat Cancer; 2014 Oct; 21(5):R371-94. PubMed ID: 25056176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone health care for patients with prostate cancer receiving androgen deprivation therapy.
    Tsang DS; Alibhai SM
    Hosp Pract (1995); 2014 Apr; 42(2):89-102. PubMed ID: 24769788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
    Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
    Anticancer Res; 2017 Jul; 37(7):3667-3671. PubMed ID: 28668858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
    Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
    Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
    Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
    BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis.
    Kim DK; Lee JY; Kim KJ; Hong N; Kim JW; Hah YS; Koo KC; Kim JH; Cho KS
    J Clin Med; 2019 Jan; 8(1):. PubMed ID: 30669289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
    Izumi K; Mizokami A; Sugimoto K; Narimoto K; Miwa S; Maeda Y; Kadono Y; Takashima M; Koh E; Namiki M
    Urology; 2009 Jun; 73(6):1342-6. PubMed ID: 19371939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.